pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table 1 Comparison of the 2022 WHO and 2022 ICC diagnostic criteria in classifying MDS subtypes with SF3B1 or TP53 mutations

MDS subtype	Commonalities	Differences
MDS subtype	Commonalities	2022 WHO	ICC
MDS-SF3B1^WHO/ICC	≥1 dysplastic lineage and cytopenia each Blasts: <5% BM, <2% PB Cytogenetics: absence of del(5q), -7/del(7q), or CK Mutations: absence of biallelic TP53	Erythroid lineage dysplasia is required Mutations: ≥5% VAF of SF3B1	Cytogenetics: absence of abn3q26.2 Mutations: ≥10% VAF of SF3B1, absence of RUNX1
MDS-LB-RS with wild-type SF3B1^WHO		Satisfied for MDS-SF3B1^WHO except for SF3B1_mut ≥15% RS	Not defined and included in MDS, NOS
MDS-biTP53^WHO/MDS with mutated TP53^ICC		≥1 dysplastic lineages and cytopenias Blasts: <20% BM and PB Genetics: ≥2 TP53 mutations, or one mutation with evidence of TP53 copy number loss or cnLOH	Not stated for dysplastic lineage/cytopenia Blasts: 0%–9% BM and PB Genetics: >10% VAF of TP53_mut (prerequisite), 2 distinct TP53_mut or 1 TP53_mut with (1) del(17p) on cytogenetics (2) VAF>50% (3) cnLOH at TP53 locus or (N/A for TP53 locus LOH status) CK often with del(17p)
MDS/AML with mutated TP53^ICC		Not defined Cases with 10–19% blasts and biallelic TP53 inactivation are classified as MDS-biTP53	Blasts: 10%–19% BM and PB Any somatic TP53 mutation (VAF>10%)

Abbreviations: ICC, International Consensus Classification; BM, bone marrow; PB, peripheral blood; CK, complex karyotype; del, deletion; VAF, variant allele frequency; abn, abnormality; LB, low blasts; RS, ring sideroblasts; NOS, not otherwise specified; cn, copy-neutral; LOH, loss of heterozygosity; mut, mutation; N/A, not available.

Ann Lab Med 2025;45:36~43 https://doi.org/10.3343/alm.2024.0079